Market cap
$320 Mln
Revenue (TTM)
$216 Mln
P/E Ratio
--
P/B Ratio
1.5
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -2.30 | -3.92 | 6.02 | -3.27 | -3.56 |
| EBIT | -34.71 | -86.99 | -125.84 | -298.00 | -234.04 |
| Net Profit | -28.71 | -129.77 | -310.61 | -364.21 | -253.32 |
| EPS | -27.08 | -125.07 | -305.65 | -360.94 | -251.73 |
| Book Value | -- | -- | -40.06 | -15.63 | -7.15 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -27.64 | -12.54 | -83.46 | -64.16 | -11.53 |
| Net Margin
| -- | -- | -127.41 | -- | -- |
| Return on equity
| -17.98 | -9.16 | -100.43 | -50.93 | -3.49 |
| Return on Capital
| -17.49 | -8.91 | -- | -49.51 | -3.42 |
| Return on Assets
| -13.67 | -6.82 | -41.56 | -38.51 | -2.90 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.04 | 0.02 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
--
|
-49.51
|
-3.42
|
0.46
|
1.19
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-100.43
Lower than Peers by 60.03
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
-100.43
|
-50.93
|
-3.49
|
0.47
|
1.22
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-41.56
Lower than Peers by 10.58
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
-41.56
|
-38.51
|
-2.90
|
0.39
|
1.02
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
-83.46
Higher than Peers by 0.15
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
-83.46
|
-64.16
|
-11.53
|
-7.24
|
4.44
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
-127.41
Lower than Peers by 34.74
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
-127.41
|
-102.02
|
-9.51
|
1.30
|
2.47
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Higher than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
6.02
Lower than Peers by 47.93
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
6.02
|
0.09
|
0.03
|
-0.24
|
-0.05
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
-125.84
Lower than Peers by 125.04
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
-125.84
|
-504.89
|
-64.28
|
-223.47
|
-73.33
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
-310.61
Lower than Peers by 303.31
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
-310.61
|
-1,066.53
|
-853.29
|
-60.02
|
-81.07
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
-305.65
Lower than Peers by 320.30
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
-305.65
|
-10.51
|
-8.43
|
-0.60
|
-0.81
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
-55.65
Lower than Peers by 45.47
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
-55.65
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
--
|
0.04
|
0.02
|
0.02
|
0.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.02
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
0.02
|
0.02
|
0.01
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.61
Lower than Peers by 4.20
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
1.61
|
2.39
|
4.39
|
4.94
|
5.68
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
1.60
Lower than Peers by 4.09
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
1.60
|
2.38
|
4.37
|
4.92
|
5.67
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
--
|
--
|
--
|
--
|
2.27
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
27.67
Higher than Peers by 8.53
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
27.67
|
25.26
|
23.70
|
17.73
|
13.17
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
0.33
Higher than Peers by 0.26
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
0.33
|
0.38
|
0.30
|
0.30
|
0.41
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
--
|
85.93
|
74.66
|
64.15
|
47.37
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
--
|
50.09
|
49.76
|
26.51
|
16.69
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
--
|
118.14
|
171.79
|
206.12
|
102.40
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
--
|
17.88
|
-47.37
|
-115.46
|
-38.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
--
|
-2.36
|
-14.78
|
96.77
|
67.35
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
1.49
Lower than Peers by 3.69
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
1.49
|
1.59
|
0.52
|
0.45
|
0.80
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
0.76
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
0.76
|
-2.13
|
5.61
|
9.75
|
-2.36
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
320
Higher than Peers by 174
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Vanda Pharmaceuticals (VNDA)
|
320
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|